Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Journal of Thrombosis and Thrombolysis

Volumn 51, Issue 4, 2021, Pages 1107-1110

  Yin, Shiyu ^a   Huang, Ming ^a   Li, Dengju ^a   Tang, Ning ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Coagulopathy; Coronavirus disease 2019; D dimer; Severe pneumonia

Indexed keywords

ANTICOAGULANT AGENT; D DIMER; HEPARIN; FIBRIN DEGRADATION PRODUCT; FIBRIN FRAGMENT D;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CONTROLLED STUDY; CORONAVIRUS DISEASE 2019; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PLATELET COUNT; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; AGE; BLOOD; BLOOD CLOTTING TEST; CHINA; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGY; ORGAN DYSFUNCTION SCORE; PATHOPHYSIOLOGY; PROCEDURES; RISK FACTOR; SEPSIS; SEX FACTOR; THROMBOPHILIA;

AGE FACTORS; AGED; BLOOD COAGULATION TESTS; CHINA; COVID-19; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; MALE; MIDDLE AGED; ORGAN DYSFUNCTION SCORES; PLATELET COUNT; PNEUMONIA; RETROSPECTIVE STUDIES; RISK FACTORS; SEPSIS; SEX FACTORS; THROMBOPHILIA;

EID: 85083238014     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-020-02105-8     Document Type: Article

References (15)

1. Chen N, Zhou M, Dong X et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513 DOI: 10.1016/S0140-6736(20)30211-7
2. Huang C, Wang Y, Li X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223):497–506 DOI: 10.1016/S0140-6736(20)30183-5
3. Tang N, Li D, Wang X, Sun Z (20220) Abnormal Coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost
4. Fung SY, Yuen KS, Ye ZW, Chan CP, Jin DY (2020) A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses. Emerg Microbes Infect 9(1):558–570 DOI: 10.1080/22221751.2020.1736644
5. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS (2006) Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia—a review. Crit Care Med 34(3):871–877 DOI: 10.1097/01.CCM.0000201882.23917.B8
6. National Health Commission of China (2020) The diagnosis and treatment plan for the novel coronavirus disease, 7th edn. National Health Commission of China, Bejing
7. Iba T, Nisio MD, Levy JH, Kitamura N, Thachil J (2017) New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey. BMJ Open 7(9):e017046 DOI: 10.1136/bmjopen-2017-017046
8. Venclauskas L, Llau JV, Jenny JY, Kjaersgaard-Andersen P, Jans Ø, ESA VTE Guidelines Task Force (2018) European guidelines on perioperative venous thromboembolism prophylaxis: day surgery and fast-track surgery. Eur J Anaesthesiol 35(2):134–138 DOI: 10.1097/EJA.0000000000000706
9. Levi M, van der Poll T (2017) Coagulation and sepsis. Thromb Res 149:38–44 DOI: 10.1016/j.thromres.2016.11.007
10. Schmitt FCF, Manolov V, Morgenstern J et al (2019) Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study. Ann Intensive Care 9(1):19 DOI: 10.1186/s13613-019-0499-6
11. Gupta N, Zhao YY, Evans CE (2019) The stimulation of thrombosis by hypoxia. Thromb Res 181:77–83 DOI: 10.1016/j.thromres.2019.07.013
12. Menter DG, Kopetz S, Hawk E et al (2017) Platelet “first responders” in wound response, cancer, and metastasis. Cancer Metastasis Rev 36(2):199–213 DOI: 10.1007/s10555-017-9682-0
13. Poterucha TJ, Libby P, Goldhaber SZ (2017) More than an anticoagulant: do heparins have direct anti-inflammatory effects? Thromb Haemost 117(3):437–444 DOI: 10.1160/TH16-08-0620
14. Aikawa N, Shimazaki S, Yamamoto Y et al (2011) Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial. Shock 35(4):349–354 DOI: 10.1097/SHK.0b013e318204c019
15. Liu XL, Wang XZ, Liu XX et al (2014) Low-dose heparin as treatment for early disseminated intravascular coagulation during sepsis: a prospective clinical study. Exp Ther Med 7(3):604–608 DOI: 10.3892/etm.2013.1466